Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Regulatory News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

5 Jan 2016 15:00

RNS Number : 9122K
Diurnal Group PLC
05 January 2016
 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Diurnal Group Plc.

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

No

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

No

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

No

An event changing the breakdown of voting rights

No

Other (please specify):

Placing

Yes

3. Full name of person(s) subject to thenotification obligation: iii

Invesco Limited

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

24 December 2015

6. Date on which issuer notified:

29 December 2015

7. Threshold(s) that is/are crossed orreached: vi, vii

5%, 10%, 11% & 12%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

GB00BDB6Q760

0

0

6,527,777

12.50%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

6,527,777

12.50%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

Invesco Asset Management Ltd - 6,527,777

Proxy Voting:

10. Name of the proxy holder:

Invesco Limited

11. Number of voting rights proxy holder will ceaseto hold:

N/A

12. Date on which proxy holder will cease to holdvoting rights:

N/A

13. Additional information:

14. Contact name:

Philippa Holmes

15. Contact telephone number:

01491 417 000

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUGUMAGUPQGCA
Date   Source Headline
7th Mar 20222:30 pmRNSScottish Medicines Consortium Update
2nd Mar 20227:00 amRNSRegulatory update on oral native testosterone
1st Mar 202210:23 amRNSTotal Voting Rights
24th Feb 202212:00 pmRNSNotice of Interim Results
10th Feb 20227:00 amRNSFirst patient dosed in Phase 2 trial
9th Feb 20227:00 amRNSIssue of Long-Term Incentive Plan awards
1st Feb 20227:00 amRNSTotal Voting Rights
31st Jan 20221:26 pmRNSPostponement of R&D Day
26th Jan 20227:00 amRNSTrading Update
24th Jan 20227:00 amRNSDiurnal to participate in Edison “Open House”
11th Jan 20227:00 amRNSOperational update
7th Jan 202212:58 pmRNSHolding(s) in Company
13th Dec 202112:46 pmRNSBlock Admission Application
2nd Dec 20217:00 amRNSNotice of R&D Day
19th Nov 202111:43 amRNSResults of AGM
16th Nov 20217:00 amRNSAlkindi approved for use in Switzerland
15th Nov 20215:20 pmRNSEton enters into US co-promotion deal
15th Nov 20217:00 amRNSDirectorate Change
8th Nov 20219:16 amRNSHolding(s) in Company
15th Oct 202111:17 amRNSHolding(s) in Company
14th Oct 20217:01 amRNSAppointment of Joint Corporate Broker
14th Oct 20217:00 amRNSAgreement signed with ExCEEd Orphan for CEE
11th Oct 20217:00 amRNSPhase 1 data for DITEST published in EJE
8th Oct 202112:24 pmRNSExercise of Options, Issue of Equity and TVR
7th Oct 202111:15 amEQSHardman & Co Research | Diurnal (DNL) Life Sciences Investor Forum
6th Oct 20213:53 pmRNSPosting of Annual Report and Notice of AGM
30th Sep 202112:08 pmRNSHolding(s) in Company
29th Sep 20212:35 pmRNSHolding(s) in Company
17th Sep 20217:00 amRNSHardman & Co Life Sciences Investor Forum
16th Sep 202110:15 amEQSHardman & Co Research: Diurnal Group (DNL): All set for three pivotal trials
15th Sep 20219:17 amRNSDirector Dealings
14th Sep 20217:00 amRNSResults for the year ended 30 June 2021
13th Sep 20217:00 amRNSCommercial launch of Efmody in the UK
1st Sep 20217:00 amRNSDiurnal launches Efmody in Germany and Austria
19th Aug 20217:00 amRNSFull Year Results Investor Presentation
12th Aug 20217:20 amEQSHardman & Co Video Event | Diurnal Group plc - Investor Forum
2nd Aug 20217:00 amRNSGrant of Deferred Share Awards
28th Jul 20217:00 amRNSBusiness and Trading Update
14th Jul 20217:00 amRNSDirector Dealings
12th Jul 20217:00 amRNSAgreement from US FDA on SPA for Chronocort
9th Jul 20218:30 amRNSDirector Dealings and Issue of Equity
7th Jul 20217:00 amRNSNotice of Full Year Results
5th Jul 20217:00 amRNSShares and AJ Bell Investor Evening Webinar
2nd Jul 20217:00 amRNSMarketing Authorisation for Efmody in GB from MHRA
29th Jun 20217:00 amRNSDistribution agreement with Er-Kim
2nd Jun 202112:19 pmRNSDirector Dealings
1st Jun 20217:00 amRNSDiurnal triggers milestone payments from Citrine
28th May 20212:33 pmRNSEuropean Commission approval received for Efmody
13th May 20217:00 amRNSCorrection: Director Dealings
12th May 20215:32 pmRNSDirector Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.